In the US alone, 12% of the population have reported using injectable weight loss drugs, such as Wegovy/Ozempic, Zepbound and Saxenda, over the past year. That's more than double the number recorded in early 2024. In European countries, demand is also on the rise: In the UK, for example, a survey found that 21% of the public had accessed an online or in-person pharmacy in the past year to obtain weight loss medication. Germans, for example, have also been keen to adopt the drugs, even if they